Peter A. McSweeney

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

Sattva S. Neelapu, Frederick L. Locke, Nancy L. Bartlett et al. · New England Journal of Medicine · 2017 · 5.9K citations · Full text

Medicine, Hematology, Oncology +16

Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial

Frederick L. Locke, Armin Ghobadi, Caron A. Jacobson et al. · The Lancet Oncology · 2018 · 2.3K citations

Medicine, Oncology, Pharmacology +12

KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma

Michael Wang, Javier Muñoz, André Goy et al. · New England Journal of Medicine · 2020 · 1.8K citations · Full text

Medicine, Hematology, Oncology +15

Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects

Peter A. McSweeney, Dietger Niederwieser, Judith A. Shizuru et al. · Blood · 2001 · 1.4K citations

Medicine, Geriatric Medicine, Hematology +13

Ipilimumab for Patients with Relapse after Allogeneic Transplantation

Matthew S. Davids, Haesook T. Kim, Pavan Bachireddy et al. · New England Journal of Medicine · 2016 · 594 citations · Full text

Medicine, Immunology, Oncology +15